What is FUSE MEDICAL INC's earnings per share (EPS)?

FUSE MEDICAL INC (FZMD) reported diluted earnings per share of $0.04 for fiscal year 2022. This represents a 300.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

FUSE MEDICAL INC (FZMD) Financials

FZMD

Trailing 12 months to June 30, 2023

Revenue $18.4M -5.8% YoY

Net Income $4.0M +315.1% YoY

EPS (Diluted) $0.04 FY2022 annual

Operating Cash Flow $19K +101.1% YoY

Market Cap $7.4M as of Sep 2, 2026

Price / Sales 0.4x on $18.4M revenue, trailing 12 months to June 30, 2023

Price / Earnings 1.9x on $4.0M net income, trailing 12 months to June 30, 2023

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2023

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2023, ended Jun 30, 2023 Reported Aug 14, 2023 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2023, filed Aug 14, 2023. Each column of the statement tables below links to the filing it was taken from.

FUSE MEDICAL INC (FZMD) reported $18.4M in revenue over the twelve months to Jun 30, 2023, down 5.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FZMD FY2022 2026-08-30

Fuse Medical’s margin-rich model still produces weak cash conversion and a balance sheet with negative equity.

FY2022 net income of $3.1M coexisted with operating cash flow of only $35K, following operating cash flow of -$1.8M in FY2021. That earnings-to-cash gap, alongside a negative operating result, indicates that reported profit was not being generated by cash-producing core operations.

Gross margin expanded from 58.5% to 61.9% even as sales contracted, pointing to cost-of-revenue improvement or a more favorable mix rather than scale-driven leverage. Operating loss narrowed to $815K as SG&A declined to $6.5M, but core operations remained unprofitable.

Liabilities exceeded assets by $311K in FY2022, leaving negative equity and showing that recorded assets did not fully cover obligations. The current ratio fell from 1.3x to 1.1x, while inventory reached $9.5M against current assets of $13.8M, tying short-term flexibility closely to inventory conversion.

Financial Health Signals

Financial health score not available

FUSE MEDICAL INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

0.93

FUSE MEDICAL INC scores 0.93, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

FUSE MEDICAL INC passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.01x

For every $1 of reported earnings, FUSE MEDICAL INC generates $0.01 in operating cash flow ($35K OCF vs $3.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

N/A

FUSE MEDICAL INC reported an operating loss of $815K against $171K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.0M

YoY+7.0%

QoQ+25.4%

5Y CAGR-2.7%

FUSE MEDICAL INC generated $5.0M in revenue in Q2 2023. This represents an increase of 7.0% from the same quarter a year earlier. Against the prior quarter it is up 25.4%.

EBITDA

$402K

YoY+2432.2%

QoQ+403.9%

FUSE MEDICAL INC's EBITDA was $402K in Q2 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 2432.2% from the same quarter a year earlier. Against the prior quarter it is up 403.9%.

Net Income

$308K

YoY+195.2%

QoQ+234.7%

FUSE MEDICAL INC reported $308K in net income in Q2 2023. This represents an increase of 195.2% from the same quarter a year earlier. Against the prior quarter it is up 234.7%.

EPS (Diluted)

Not reported for Q2 2023.

Cash & Balance Sheet

Cash & Debt

$253K

YoY-58.0%

QoQ+20.1%

5Y CAGR-18.2%

FUSE MEDICAL INC held $253K in cash as of Q2 2023; long-term debt is not reported for that period.

Shares Outstanding

74M

YoY+1.4%

QoQ0.0%

5Y CAGR+1.0%

10Y CAGR+35.4%

FUSE MEDICAL INC had 74M shares outstanding in Q2 2023. This represents an increase of 1.4% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2023.

Dividends Per Share

Not reported for Q2 2023.

Margins & Returns

Gross Margin

69.4%

YoY+6.3pp

QoQ-1.3pp

5Y change+35.4pp

FUSE MEDICAL INC's gross margin was 69.4% in Q2 2023, indicating the percentage of revenue retained after direct costs. This is up 6.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.3 percentage points.

Operating Margin

7.4%

YoY+8.5pp

QoQ+11.5pp

5Y change+41.7pp

FUSE MEDICAL INC's operating margin was 7.4% in Q2 2023, reflecting core business profitability. This is up 8.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 11.5 percentage points.

Net Margin

6.2%

YoY+13.1pp

QoQ+11.9pp

5Y change+34.4pp

FUSE MEDICAL INC's net profit margin was 6.2% in Q2 2023, showing the share of revenue converted to profit. This is up 13.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 11.9 percentage points.

Return on Equity

Not reported for Q2 2023.

Capital Allocation

None of these metrics is reported for Q2 2023.

FZMD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FZMD quarterly income statement

Metric	TTM	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$18.4M	$18.6M-8.7%	$20.4M-4.6%	$21.4M-6.6%	$22.9M-13.1%	$26.3M-0.2%	$26.4M+2.9%	$25.7M+1430.9%	$1.7M+78.2%	$941K-11.2%	$1.1M	N/A	N/A
Cost of Revenue	$6.3M	$7.1M-16.2%	$8.5M-2.5%	$8.7M-26.1%	$11.8M-11.9%	$13.4M-8.4%	$14.6M+29.5%	$11.3M+1594.6%	$664K+36.9%	$485K+138.5%	$204K	N/A	N/A
Gross Profit	$12.1M	$11.5M-3.3%	$11.9M-6.0%	$12.7M+14.1%	$11.1M-14.3%	$13.0M+9.8%	$11.8M-17.9%	$14.4M+1323.4%	$1.0M+122.2%	$456K-46.8%	$856K	N/A	N/A
SG&A Expenses	$6.7M	$6.5M-6.8%	$7.0M+7.2%	$6.5M-22.7%	$8.5M0.0%	$8.5M+59.3%	$5.3M+27.4%	$4.2M	N/A	N/A	N/A	N/A	N/A
Operating Income	-$122K	-$815K+62.9%	-$2.2M-113.6%	-$1.0M+76.4%	-$4.3M-122.1%	-$2.0M-328.0%	$859K-72.9%	$3.2M+498.2%	-$794K+40.5%	-$1.3M-406.1%	$436K	N/A	-$123K
EBITDA	N/A	-$678K+68.2%	-$2.1M-130.3%	-$924K+78.2%	-$4.2M-122.3%	-$1.9M-318.5%	$873K-72.6%	$3.2M+513.7%	-$769K+41.8%	-$1.3M-402.8%	$436K	N/A	N/A
Interest Expense	$213K	$171K+119.0%	$78K-17.6%	$95K-21.9%	$122K-9.2%	$134K-17.1%	$162K+10.0%	$147K+2088.9%	$7K-90.6%	$72K+10604.3%	$669	N/A	N/A
Income Tax	$26K	$24K+33.5%	$18K-6.7%	$19K-97.6%	$781K+301.9%	-$387K-1047.6%	$41K-20.9%	$52K	$0	N/A	N/A	N/A	N/A
Net Income	$4.0M	$3.1M+295.1%	-$1.6M-10.8%	-$1.4M+56.8%	-$3.3M-183.8%	$4.0M+465.6%	$700K-76.8%	$3.0M+476.3%	-$802K+43.0%	-$1.4M-422.7%	$435K	N/A	-$122K
EPS (Basic)	N/A	$0.04+300.0%	-$0.020.0%	-$0.02+60.0%	-$0.05-183.3%	$0.06+50.0%	$0.04-90.5%	$0.42	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	$0.04+300.0%	-$0.020.0%	-$0.02+60.0%	-$0.05-200.0%	$0.05	$0.04	$0.33	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	78M+10.7%	70M+0.1%	70M0.0%	70M-5.0%	74M	19M	9M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K	Q3'2110-Q
Revenue	$5.0M+7.0%	$4.0M-12.5%	$4.9M-19.4%	$4.5M+6.7%	$4.7M-17.6%	$4.6M+2.6%	$6.1M-13.6%	$4.3M-25.9%
Cost of Revenue	$1.5M-11.3%	$1.2M-33.0%	$2.2M-15.3%	$1.5M-20.4%	$1.7M-22.3%	$1.7M-6.0%	$2.5M-11.4%	$1.9M-8.9%
Gross Profit	$3.5M+17.8%	$2.8M+0.2%	$2.7M-22.3%	$3.1M+27.9%	$2.9M-14.5%	$2.8M+8.7%	$3.5M-15.1%	$2.4M-35.3%
SG&A Expenses	$1.6M+13.7%	$1.7M-0.2%	$1.7M-15.0%	$1.7M+9.5%	$1.4M-29.6%	$1.7M+19.1%	$2.0M+31.4%	$1.6M+13.1%
Operating Income	$369K+814.6%	-$166K+62.2%	-$370K+43.9%	$45K+106.6%	-$52K+87.9%	-$439K-2.0%	-$659K-228.6%	-$681K-737.9%
EBITDA	$402K+2432.2%	-$132K+67.3%	-$383K+39.9%	$127K+119.1%	-$17K+95.8%	-$404K+2.2%	-$638K-219.8%	-$666K-612.4%
Interest Expense	$54K+47.9%	$57K+73.5%	$55K+78.7%	$47K+275.6%	$37K+127.6%	$33K+73.5%	$31K+58.7%	$13K-39.3%
Income Tax	$7K+40.1%	$6K+15.2%	$6K+27.0%	$7K+105.8%	$5K+7.1%	$5K+11.4%	$5K-34.7%	$4K-37.5%
Net Income	$308K+195.2%	-$228K+52.1%	$3.9M+1209.7%	-$9K+98.7%	-$323K-277.8%	-$476K-5.1%	-$352K-281.0%	-$697K-966.1%
EPS (Basic)	$0.00	$0.00+100.0%	$0.05	$0.00+100.0%	$0.00	-$0.01	$0.00	-$0.01
EPS (Diluted)	N/A	$0.00+100.0%	N/A	N/A	N/A	-$0.01	$0.00	-$0.01
Diluted Shares (Avg)	78M	70M0.0%	N/A	N/A	N/A	70M	N/A	70M-6.4%

Not reported in any period shown, so not listed: R&D Expenses.

FZMD Balance Sheet

FZMD quarterly balance sheet

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$19.8M+8.0%	$18.3M+5.1%	$17.4M-5.2%	$18.4M-17.1%	$22.2M+15.2%	$19.2M-1.7%	$19.6M+4400.1%	$435K-20.3%	$546K-2.4%	$559K+10024.1%	$6K-91.5%	$65K
Current Assets	$13.8M+7.3%	$12.8M+1.6%	$12.6M-11.4%	$14.2M-17.1%	$17.2M-4.8%	$18.0M-3.7%	$18.7M+4512.6%	$406K-17.8%	$494K-11.4%	$558K+9997.2%	$6K-91.5%	$65K
Cash & Equivalents	$148K-73.3%	$553K-53.4%	$1.2M+8.0%	$1.1M+30.2%	$844K+4.9%	$805K+3.4%	$778K+195.3%	$264K+290.2%	$68K-76.9%	$292K+8792.5%	$3K-93.8%	$53K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$9.5M+8.7%	$8.7M+25.1%	$7.0M-11.1%	$7.9M-29.1%	$11.1M+4.2%	$10.6M-7.0%	$11.4M+13970.9%	$81K-38.2%	$131K-35.4%	$203K	N/A	N/A
Accounts Receivable	$4.0M+13.3%	$3.5M-20.3%	$4.4M-15.7%	$5.2M+0.5%	$5.2M-20.5%	$6.6M+1.0%	$6.5M+2083.9%	$298K+51.9%	$196K+107.3%	$95K	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M-32.1%	$2.9M+254.0%	$821K0.0%	$821K	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$20.1M-7.7%	$21.7M+11.3%	$19.5M-0.4%	$19.6M-5.3%	$20.7M-24.0%	$27.2M+203.3%	$9.0M+218.7%	-$7.6M-2277.3%	$347K+20.4%	$289K+1715.2%	-$18K-325.4%	$8K
Current Liabilities	$12.4M+24.6%	$9.9M+37.2%	$7.2M-8.9%	$8.0M+11.7%	$7.1M-10.8%	$8.0M-11.1%	$9.0M+2619.7%	$330K-5.0%	$347K+20.4%	$289K+480.4%	$50K+527.3%	$8K
Non-Current Liabilities	$7.7M-34.8%	$11.8M-4.0%	$12.3M+5.5%	$11.6M-14.3%	$13.6M-29.4%	$19.2M	$0+100.0%	-$7.9M	$0	$0+100.0%	-$68K	$0
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$100K	N/A	N/A	N/A	N/A
Total Equity	-$311K+90.9%	-$3.4M-62.4%	-$2.1M-72.9%	-$1.2M-183.3%	$1.5M+118.4%	-$8.0M-175.3%	$10.6M+32.5%	$8.0M+3929.2%	$199K-26.7%	$271K+1057.5%	$23K-59.2%	$57K
Retained Earnings	-$2.5M+55.2%	-$5.6M-39.4%	-$4.0M-55.2%	-$2.6M-460.2%	$721K	N/A	-$2.9M-25.3%	-$2.3M-53.0%	-$1.5M-691.8%	$256K+107.8%	-$3.3M-3.2%	-$3.2M

Metric	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K	Q3'2110-Q
Total Assets	$19.3M+1.4%	$18.4M+3.7%	$19.8M+8.0%	$19.2M+6.5%	$19.1M+5.8%	$17.8M+1.8%	$18.3M+5.1%	$18.0M+6.0%
Current Assets	$12.8M-1.6%	$12.2M+1.6%	$13.8M+7.3%	$13.0M+1.2%	$13.0M+1.9%	$12.0M-4.4%	$12.8M+1.6%	$12.9M+9.2%
Cash & Equivalents	$253K-58.0%	$211K-59.6%	$148K-73.3%	$506K-71.3%	$604K-55.5%	$522K-63.1%	$553K-53.4%	$1.8M+14.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$9.0M-3.5%	$9.2M-1.2%	$9.5M+8.7%	$9.9M+15.0%	$9.4M+12.6%	$9.3M+22.0%	$8.7M+25.1%	$8.6M+22.7%
Accounts Receivable	$3.4M+15.8%	$2.8M+27.6%	$4.0M+13.3%	$2.6M+6.8%	$3.0M-2.9%	$2.2M-38.0%	$3.5M-20.3%	$2.5M-23.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%
Total Liabilities	$19.5M-14.7%	$19.0M-12.0%	$20.1M-7.7%	$23.1M+9.0%	$22.9M+11.9%	$21.6M+8.3%	$21.7M+11.3%	$21.1M+8.9%
Current Liabilities	$12.1M+6.5%	$11.3M+15.7%	$12.4M+24.6%	$11.5M+34.7%	$11.3M+38.2%	$9.8M+28.0%	$9.9M+37.2%	$8.5M+14.8%
Non-Current Liabilities	$7.5M-35.4%	$7.7M-34.8%	$7.7M-34.8%	$11.6M-8.2%	$11.6M-5.6%	$11.8M-4.0%	$11.8M-4.0%	$12.6M+5.3%
Total Equity	-$232K+94.5%	-$539K+86.2%	-$311K+90.9%	-$3.9M-23.8%	-$4.2M-70.9%	-$3.9M-59.0%	-$3.4M-62.4%	-$3.1M-29.2%
Retained Earnings	-$2.4M+59.8%	-$2.7M+54.0%	-$2.5M+55.2%	-$6.1M-15.4%	-$6.1M-32.9%	-$6.0M-33.3%	-$5.6M-39.4%	-$5.3M-24.7%

Not reported in any period shown, so not listed: Long-Term Debt.

FZMD Cash Flow Statement

FZMD quarterly cash flow statement

Metric	TTM	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$19K	$35K+102.0%	-$1.8M-851.4%	$237K+5093.8%	-$5K-100.2%	$2.5M+54.6%	$1.6M-42.5%	$2.8M+843.8%	-$375K+67.9%	-$1.2M-465.7%	$320K	N/A	-$134K
Depreciation & Amortization	N/A	$137K+103.1%	$68K-35.1%	$104K-2.7%	$107K+115.5%	$50K+242.2%	$15K-23.9%	$19K-23.9%	$25K+88.8%	$13K+4642.9%	$280	N/A	N/A
Stock-Based Compensation	N/A	$23K-91.1%	$258K-53.4%	$553K-11.9%	$628K-24.8%	$835K+1859.5%	$43K-32.4%	$63K-84.9%	$418K	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	$21K+35.5%	$15K-63.4%	$42K+105.8%	$20K	N/A	$8K-86.4%	$61K+3357.4%	$2K	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	$216K+1176.4%	-$20K-100.8%	$2.4M+53.9%	$1.6M	N/A	-$383K+68.8%	-$1.2M-486.9%	$318K	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	-$21K-35.5%	-$15K+85.4%	-$105K-804.5%	-$12K-101.8%	$655K+9452.0%	-$7K+90.0%	-$70K-3888.3%	-$2K	N/A	N/A
Financing Cash Flow	-$369K	-$440K-138.5%	$1.1M+995.6%	-$128K-146.4%	$275K+111.8%	-$2.3M-49.1%	-$1.6M+46.5%	-$2.9M-1008.1%	$323K-75.1%	$1.3M+1569.8%	-$88K	N/A	N/A

Metric	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K	Q3'2110-Q
Operating Cash Flow	-$99K+59.7%	$331K-33.0%	-$831K+58.6%	$618K+896.4%	-$246K-315.8%	$494K+793.0%	-$2.0M-787.6%	$62K-85.3%
Depreciation & Amortization	$33K-4.9%	$33K-2.8%	-$89K-525.3%	$82K+467.2%	$34K+122.5%	$34K+104.8%	$21K+3.9%	$14K-37.8%
Stock-Based Compensation	N/A	N/A	N/A	N/A	N/A	$13K-88.9%	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	$521K	-$139K	$139K	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	$98K	-$385K	$355K	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	-$521K	$139K	-$139K	N/A	N/A
Financing Cash Flow	$142K-56.8%	-$268K+49.0%	-$47K-106.0%	-$196K	$328K	-$525K-399.9%	$798K+738.2%	N/A

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

FZMD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FZMD quarterly financial ratios

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	61.9%+3.4pp	58.5%-0.9pp	59.4%+10.7pp	48.6%-0.7pp	49.3%+4.5pp	44.8%-11.4pp	56.1%-4.2pp	60.4%+12.0pp	48.4%-32.4pp	80.8%	N/A	N/A
Operating Margin	-4.4%+6.4pp	-10.8%-5.9pp	-4.8%+14.2pp	-19.0%-11.6pp	-7.4%-10.7pp	3.3%-9.1pp	12.3%+59.7pp	-47.4%	-141.8%	41.2%	N/A	N/A
Net Margin	16.6%+24.4pp	-7.8%-1.1pp	-6.7%+7.8pp	-14.5%-29.5pp	15.0%+12.4pp	2.6%-9.1pp	11.8%+59.6pp	-47.8%	-149.3%	41.1%	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	269.8%	N/A	28.5%+38.5pp	-10.0%+697.8pp	-707.8%-868.7pp	160.8%	N/A	-213.0%
Return on Assets	15.7%+24.3pp	-8.7%-0.5pp	-8.2%+9.8pp	-18.0%-35.9pp	17.8%+14.2pp	3.6%-11.8pp	15.4%+199.7pp	-184.3%+73.1pp	-257.4%-335.2pp	77.8%	N/A	-187.2%
Current Ratio	1.11-0.2x	1.29-0.5x	1.740.0x	1.79-0.6x	2.41+0.2x	2.26+0.2x	2.09+0.9x	1.23-0.2x	1.42-0.5x	1.93+1.8x	0.11-8.1x	8.24
Debt-to-Equity	N/A	N/A	N/A	N/A	14.12	N/A	0.85+0.8x	0.01-1.7x	1.75+0.7x	1.07	N/A	0.14
Asset Turnover	0.94-0.2x	1.12-0.1x	1.230.0x	1.25+0.1x	1.19-0.2x	1.37+0.1x	1.31-2.5x	3.85+2.1x	1.72-0.2x	1.89	N/A	N/A
FCF Margin	N/A	N/A	1.0%+1.1pp	-0.1%-9.3pp	9.3%+3.3pp	6.0%	N/A	-22.9%	-130.7%	30.0%	N/A	N/A

Metric	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K	Q3'2110-Q
Gross Margin	69.4%+6.3pp	70.7%+9.0pp	55.9%-2.1pp	67.3%+11.1pp	63.1%+2.3pp	61.7%+3.5pp	58.0%-1.1pp	56.2%-8.2pp
Operating Margin	7.4%+8.5pp	-4.2%+5.5pp	-7.6%+3.3pp	1.0%+17.0pp	-1.1%+6.4pp	-9.6%+0.1pp	-10.9%-18.2pp	-16.0%-17.9pp
Net Margin	6.2%+13.1pp	-5.7%+4.7pp	80.0%+85.8pp	-0.2%+16.2pp	-6.9%-5.4pp	-10.5%-0.3pp	-5.8%-8.6pp	-16.4%-17.8pp
Return on Assets	1.6%+3.3pp	-1.2%+1.4pp	19.8%+21.7pp	-0.1%+3.8pp	-1.7%-1.2pp	-2.7%-0.1pp	-1.9%-3.0pp	-3.9%-4.3pp
Current Ratio	1.06-0.1x	1.08-0.1x	1.11-0.2x	1.14-0.4x	1.15-0.4x	1.23-0.4x	1.29-0.5x	1.51-0.1x
Asset Turnover	0.260.0x	0.220.0x	0.25-0.1x	0.240.0x	0.24-0.1x	0.260.0x	0.33-0.1x	0.24-0.1x
FCF Margin	N/A	N/A	N/A	2.1%	-8.3%	7.8%	N/A	N/A

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Note: Shareholder equity is negative (-$311K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
FUSE MEDICAL INC FZMD	FY2022	$18.6M	$3.1M	16.6%	$7.4M	—
ALR TECHNOLOGIES SG LTD ALRTF	FY2025	N/A	N/A	N/A	$12.1M	—
ADM TRONICS UNLTD INC ADMT	FY2026	$3.3M	-$100K	-3.0%	$3.4M	—
REMSLEEP HOLDINGS INC RMSL	FY2025	$17K	N/A	N/A	$3.3M	—
STIMCELL ENERGETICS INC STME	FY2026	N/A	N/A	N/A	$4.7M	—

Where FUSE MEDICAL INC Ranks

Frequently Asked Questions

What is FUSE MEDICAL INC's annual revenue?

FUSE MEDICAL INC (FZMD) reported $18.6M in total revenue for fiscal year 2022. This represents a -8.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is FUSE MEDICAL INC's revenue growing?

FUSE MEDICAL INC (FZMD) revenue declined by 8.7% year-over-year, from $20.4M to $18.6M in fiscal year 2022.

Is FUSE MEDICAL INC profitable?

Yes, FUSE MEDICAL INC (FZMD) reported a net income of $3.1M in fiscal year 2022, with a net profit margin of 16.6%.

What is FUSE MEDICAL INC's EBITDA?

FUSE MEDICAL INC (FZMD) had EBITDA of -$678K in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

What is FUSE MEDICAL INC's gross margin?

FUSE MEDICAL INC (FZMD) had a gross margin of 61.9% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.

What is FUSE MEDICAL INC's operating margin?

FUSE MEDICAL INC (FZMD) had an operating margin of -4.4% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.

What is FUSE MEDICAL INC's net profit margin?

FUSE MEDICAL INC (FZMD) had a net profit margin of 16.6% in fiscal year 2022, representing the share of revenue converted into profit after all expenses.

What is FUSE MEDICAL INC's operating cash flow?

FUSE MEDICAL INC (FZMD) generated $35K in operating cash flow during fiscal year 2022, representing cash generated from core business activities.

What are FUSE MEDICAL INC's total assets?

FUSE MEDICAL INC (FZMD) had $19.8M in total assets as of fiscal year 2022, including both current and long-term assets.

How many shares does FUSE MEDICAL INC have outstanding?

FUSE MEDICAL INC (FZMD) had 74M shares outstanding as of fiscal year 2022.

What is FUSE MEDICAL INC's current ratio?

FUSE MEDICAL INC (FZMD) had a current ratio of 1.11 as of fiscal year 2022, which is considered adequate.

What is FUSE MEDICAL INC's return on assets (ROA)?

FUSE MEDICAL INC (FZMD) had a return on assets of 15.7% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.

What is FUSE MEDICAL INC's P/E ratio?

FUSE MEDICAL INC (FZMD) trades at 1.9x earnings, its market capitalization divided by net income of $4.0M net income, trailing 12 months to June 30, 2023. The market capitalization is $7.4M as of Sep 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is FUSE MEDICAL INC's price-to-sales ratio?

FUSE MEDICAL INC (FZMD) trades at 0.4x sales, its market capitalization divided by revenue of $18.4M revenue, trailing 12 months to June 30, 2023. The market capitalization is $7.4M as of Sep 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is FUSE MEDICAL INC's debt-to-equity ratio negative or not reported?

FUSE MEDICAL INC (FZMD) has negative shareholder equity of -$311K as of fiscal year 2022, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is FUSE MEDICAL INC's Altman Z-Score?

FUSE MEDICAL INC (FZMD) has an Altman Z-Score of 0.93, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is FUSE MEDICAL INC's Piotroski F-Score?

FUSE MEDICAL INC (FZMD) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are FUSE MEDICAL INC's earnings high quality?

FUSE MEDICAL INC (FZMD) has an earnings quality ratio of 0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can FUSE MEDICAL INC cover its interest payments?

FUSE MEDICAL INC (FZMD) reported an operating loss of $815K against $171K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.